Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.735
-0.075 (-4.14%)
Aug 28, 2026, 1:40 PM EDT - Market open

Annovis Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.764.486.76.2496.06
Research & Development
43.7725.222038.7916.528.48
Operating Expenses
49.5329.726.6945.0425.5114.54
Operating Income
-49.53-29.7-26.69-45.04-25.51-14.54
Interest & Investment Income
0.620.70.330.670.180.01
Other Non Operating Income (Expenses)
-0.610.141.77-11.84-0.04
Pretax Income
-49.52-28.85-24.59-56.2-25.33-14.49
Net Income
-49.52-28.85-24.59-56.2-25.33-14.49
Net Income to Common
-49.52-28.85-24.59-56.2-25.33-14.49
Net Income Growth
------
Shares Outstanding (Basic)
282112988
Shares Outstanding (Diluted)
282112988
Shares Change
73.71%67.97%35.60%10.55%7.03%20.88%
EPS (Basic)
-1.79-1.40-2.02-6.23-3.10-1.90
EPS (Diluted)
-1.79-1.40-2.31-6.23-3.10-1.90
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBIT
-49.53-29.7-26.69-45.04-25.51-14.54
SEC Filings: 10-K · 10-Q